The data were expressed as mean and standard deviation, and the differences between the means were established using Student (t) test. P-value ≤ 0.05 indicated statistical significance. Results: The mean levels of lysate and sputum hBD1 were not significantly different in newly diagnosed DS-TB patients (D 0 )compared with control (p > 0.05). Whereas, the mean levels of lysate and sputum hBD1 were significantly higher in newly diagnosed MDR-TB patients (M 0 ) compared with newly diagnosed DS-TB patients (D 0 )or control (p < 0.05). Conclusion: Due to the higher levels of hBD1 in the sputum and lysate of M 0 than in D 0 , one might conclude that there is a relationship between chronicity of PTB and hBD1 level.
Introduction
Tuberculosis (TB) is an infectious disease caused in humans by several strains of mycobacterium, especially Mycobacterium tuberculosis (M. tb) [1] . Globally, TB has remained a major health problem that is endemic in most developing countries of the world and responsible for ill health among millions of people. Nigeria is ranked fourth among the 22 countries with a high burden of TB in the world with a prevalence of 330 per 100,000 [2] . There is also an increasing incident of MDR-TB in Nigeria which is jeopardising the efforts of TB control [2] . Among reasons why M. tb is a major health problem globally is due to the occurrence of drug resistant strains of M. tb [3] .
Resistance to TB drugs could result from inappropriate treatment with a single anti-TB drug (usually isoniazid), wrong-drug prescription leading to ineffective treatment and may also be due to the patient not taking the medication correctly, which can be due to a variety of reasons, including cost or scarcity of medicines, patient's forgetfulness, or patient stopping treatment early because they feel better [4] . None of these reasons addressed innate intracellular components of cells involved in combating M. tb infection.
Transmission of M. tb is via inhaled air and as M. tb reaches the pulmonary alveoli, phagocytosis by alveolar macrophages and dendritic cells (DCs) is the first event in the non-specific host-pathogen interaction [5, 6] . Alveolar macrophages and DCs recognize M. tb through pattern recognition receptors (PRRs), such as pathogen-associated molecular patterns (PAMPs), which trigger an intracellular signalling cascade in the alveolar macrophages, leading to phagocytic activity [7, 8] .
Anti-microbial peptides (AMPs), which include defensins, have been identified as key elements in the innate host defence against infections [9] . Defensins possesses and exerts antimicrobial and cytotoxic activities against microorganisms especially during mycobacterium infection [10] . Apart from their antimicrobial abilities, defensins also act as chemo-attractants to immature DCs and T cells [11] .
Human β-defensins (hBD) are expressed in all human epithelial tissues [12] as one of the products of phagocytic leucocytes, especially at the site of microbial colonisation [13] . Both hBD1 and hBD2 genes are also expressed in human trachea and lung and are believed to contribute to antimicrobial defence in the respiratory tract [14] . Since M.
tb inhabit lungs and certain leucocytes where defensins are produced, there is a need to determine the levels of human defensin in the local environments (monocytes and sputum), where M. tb normally infect.
Materials and Methods

Study participants
This is a case-control study that involved the recruitment of 90 participants aged between 15 and 64 years. After obtaining a written informed consent for this study, the participants were divided into three groups that comprised of 30 multi-drug-resistant TB (MDR-TB) patients, 30 drug-sensitive TB patients (DS-TB), and 30 non-TB, apparently healthy, individuals as controls. The MDR-TB patients were diagnosed as being infected with isoniazid and rifampicin-resistant strains of M. tb with the aid of their clinical history, chest X-ray and GENE Xpert® test. After which they were admitted into the MDR-TB centre, University College Hospital (UCH) Ibadan, Nigeria for anti-TB treatment. As for the DS-TB patients, they were recruited from the Medicine Out- 
C). Student t-test was used to
compare two mean values; p-value less than 0.05 was considered significant.
Results
As shown in Table 1 , the mean levels of mononuclear cell lysate and sputum hBD1 in control, D 0 and M 0 were compared in Table 1 . The mean levels of lysate and sputum hBD1 were not significantly different in D 0 when compared with the controls. The mean levels of WBC lysate and sputum hBD1 were significantly higher in M 0 compared with D 0 or control. However, the mean concentration of sputum hBD1 in M 0 was higher than the level in the lysate. The reverse was the case in other groups. 
Discussion
Defensins, especially β-defensins, are known as endogenous antibiotics [15] that are involved in antimycobacterial defence in the local environment, especially during the inflammation and colonisation phase of mycobacterial infection [13] . Yet, studies on the levels of hBD 1 in the lysate and sputum in TB patients is lacking, though reported in the fluids of patients having other conditions apart from TB [16] [17] [18] . Non-significant differences observed when the mean levels of lysate and sputum hBD1 in D 0 were compared with the control could be attributed to the early or nonsevere phase of the M. tb infection in the patients. There is supporting evidence from the studies conducted by Ertugrul et al [19] and Kaltsa et al [20] , which reported higher levels of hBD1 in chronic periodontitis patients compared with patients having gingivitis and elevated levels of hBD1 in patients with cirrhosis when compared with hepatitis patients and control.
One of the sites of β-defensins production is the epithelial cells of the lungs where it acts as defence to mycobacterial infection and furthermore inhibits mycobacterial hBD1 is mainly expressed by epithelial cells, tissues and salivary glands, especially in the local environment of the infection, which is in the epithelial of the lungs. This could also account for higher level of sputum hBD1 compared with monocyte lysate hBD1.
Conclusion
1. Since the levels sputum and lysate hBD1 were higher in TB patients than normal individuals, it shows that hBD1 might be involved in combating TB and may be used as a therapeutic target for treating TB.
2. There is an association between and TB severity and hBD1.
